DT2219ARL
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DT2219ARL, covering 2017-12-02 to 2017-12-02. Get the full timeline:
Most recent: Clinical Trial Update: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma [Phase 1]